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SUMMARY
Introduction Angiotensin-converting enzyme (ACE) inhibitors represent a significant group of drugs 
primarily used in the treatment of hypertension and congestive heart failure.
Objective Selected ACE inhibitors (enalapril, quinapril, fosinopril, lisinopril, cilazapril) were studied in 
order to establish a fast and easy estimation method of their plasma protein binding degree based on 
their lipophilicity data.
Methods Chromatographic hydrophobicity data (parameter C
0
) were obtained on cellulose layers under 
conditions of normal-phase thin-layer chromatography (NPTLC), using different binary solvent systems. 
The ACE inhibitors lipophilicity descriptors (logP) values were calculated using the software package 
Virtual Computational Chemistry Laboratory. The ACE inhibitors plasma protein binding data were col-
lected from relevant literature.
Results ACE inhibitors protein binding data varied from negligible (lisinopril) to 99% (fosinopril). The 
calculated lipophilicity descriptors, logP
KOWWIN 
values ranged from -0.94 (lisinopril) to 6.61 (fosinopril). 
Good correlations were established between plasma protein binding values and calculated logP
KOWWIN 
values (R2=0.8026) as well as chromatographic hydrophobicity data, C
0
 parameters (R2=0.7662). Even 
though good correlation coefficients (R2) were obtained in both relations, unacceptable probability 
value with p>0.05 was found in relation between protein binding data and calculated logP
KOWWIN
 values. 
Subsequently, taking into consideration the request for probability value lower than 0.05, a better rela-
tionship was observed between protein binding data and chromatographically obtained hydrophobicity 
parameters C
0
 values.
Conclusion Cellulose layers are easily available and cost effective sorbent to assess hydrophobicity. 
Experimentally obtained data on ACE inhibitors hydrophobicity and plasma protein binding estimation 
are important parameters in evaluating bioavailability of these drugs.
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INTRODUCTION
High-throughput evaluation of drug’s proper-
ties - absorption, distribution, metabolism and 
elimination (ADME), is crucial in its discovery 
and design process. The number of molecu-
lar physicochemical properties (lipophilicity, 
solubility, molecular weight, volume of drug 
molecule, polar surface area) plays important 
role in drug’s ADME characteristics, as well as 
in plasma protein binding (PPB) degree [1, 2, 
3]. Lipophilicity is one of the most important 
properties, since lipophilic molecules exhibit 
better absorption, penetration into tissues 
and a higher degree of distribution. Also, it is 
well-known that more lipophilic drugs exert a 
higher degree of protein binding in comparison 
to less lipophilic ones with similar properties 
[1, 2, 3].
Drug molecules are in vivo either bound to 
plasma proteins and lipids, to proteins and lip-
ids in tissues, or they are free, that is, unbound, 
and diffuse among the aqueous environment 
of blood and tissues. Depending on the spe-
cific affinity for plasma protein, the portion of 
the bound and unbound drug may differ. The 
PPB degree significantly influences drug’s ef-
ficiency. The less bound drug passes through 
cell membranes or diffuses and exhibits phar-
macologic effects more efficiently. Also, PPB 
can influence the drug’s biological half-life in 
the body since bound portion may act as a res-
ervoir from which the drug is slowly released 
as the unbound form [4, 5].
Angiotensin-converting enzyme (ACE) in-
hibitors are widely used for treating hyperten-
sion, congestive heart failure and renal failure 
[5, 6, 7]. They exert antihypertensive effect 
by blocking the conversion of angiotensin I 
to angiotensin II, lowering arteriolar resist-
ance, increasing venous capacity, increasing 
natriuresis and downregulating sympathetic 
adrenergic activity. They inhibit cardiac and 
vascular remodeling associated with chronic 
hypertension, heart failure, and myocardial 
infarction, reduce ventricular preload and af-
terload, cardiac output, cardiac index, stroke 
work and volume. Furthermore, they cause 
selective dilatation of efferent renal arterioles 
lowering renovascular resistance. In addition 
to antihypertensive, ACE inhibitors also exhibit 
antiproliferative, antiaterosclerotic and fibrino-
lytic effects. In hypertensive patients with renal 
failure, particularly of diabetic etiology, ACE 
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inhibitors are used as drugs of choice because, in addition 
to antihypertensive effects, they attenuate the progression 
of microalbuminuria and proteinuria [8-11].
According to the available literature, a number of au-
thors investigated the relationship between lipophilicity 
and ACE inhibitors pharmacological activity, duration of 
action and absorption [12, 13, 14]. In our previous studies 
of ACE inhibitors we reported their lipophilic properties 
under different chromatographic conditions [15, 16, 17]. 
Also, in our recently published studies we presented cor-
relations between reversed-phase chromatographic hydro-
phobicity data and ACE inhibitors absorption values [18], 
as well as their plasma protein binding data [19].
OBjECTIvE
In continuation of our previous investigations the aim 
of this study was to assess relationship between ACE in-
hibitors lipophilicity data, experimentally obtained under 
conditions of normal-phase thin-layer chromatography 
(NP-TLC) on cellulose layers, and their plasma protein 
binding properties. The main topic was to establish the 
fast, easy, cost-effective approach enabling estimation of 
protein binding degree of ACE inhibitors.
METHODS
Based on the differences in chemical structure, ACE in-
hibitors can be distributed into three groups: with sulfhy-
dryl group (represented by captopril), with carboxyl group 
(represented by enalapril) and with phosphinic acid group 
(represented by fosinopril) [5].
In this study the following ACE inhibitors were inves-
tigated:
1. enalapril maleate, (S)-1-[N-[1-(ethoxycarbonyl)-3-
phenylpropyl]-L-alanyl]-L-proline maleate;
2. quinapril hydrochloride, [3S-[2[R*(R*)],3R*]]-
2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-
oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic 
acid hydrochloride;
3. fosinopril sodium, (4S)-4-Cyclohexyl–1-[[(R)-[(1S)-
2-methyl-1-(1-oxopropoxy)- propoxy](4-phenylbutyl) 
phosphinyl]acetyl]-L-proline, sodium salt;
4. lisinopril dihydrate, (S)-1-[N2-(1-carboxy-3-
phenylpropyl)-L-lysyl]-L-proline dihydrate;
5. cilazapril monohydrate, [1S-[1α,9α (R*)]]-9-[[1-
(ethoxycarbonyl)-3-phenylpropyl] amino]octahydro-10-
oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid 
monohydrate.
Aiming to provide a fast, high-throughput technique 
for modeling of PPB with lipophilicity, we selected these 
compounds as representative ACE inhibitors according to 
their PPB values collected from relevant references [5, 20], 
ranging from negligible (lisinopril) to 99% (fosinopril), 
and their lipophilicity, logPKOWWIN values, calculated us-
ing software package Virtual Computational Chemistry 
Laboratory [21] ranging from -0.94 (lisinopril) to 6.61 
(fosinopril). The values of PPB and lipophilicity of ACE 
inhibitors which were not included in this study are within 
these ranges. Additionally, captopril was excluded from the 
proposed model since it belongs to the sulfhydryl group of 
ACE inhibitors, with a notably different structure which 
leads to significant differences in behavior under chroma-
tographic conditions.
The normal-phase thin-layer chromatography ex-
periments were performed on cellulose, 10×10 cm, (Art. 
105552, Merck, Germany) layers. The plates were spotted 
with 2 μL aliquots of freshly prepared ethanolic solutions 
of enalapril, quinapril, fosinopril and cilazapril and aque-
ous solution of lisinopril (2 mg/mL) and developed by the 
ascending technique. Several non-aqueous binary solvent 
systems were used with varying quantities (volume frac-
tion) of components (Table 1). All components of mo-
bile phases were of the analytical grade of purity. After 
development, the detection was performed by exposing 
the plates to iodine vapor. The ratio between the distance 
that each compound travelled and the distance that solvent 
front travelled presented the RF values. All investigations 
were performed at room temperature (22±2°C).
The RM values, representing the measure of compounds 
chromatographic behavior, were calculated for each sol-
ute in each mobile phase according to the Bate-Smith and 
Westall equation RM=log (1/RF - 1) [22]. The retention be-
havior of investigated substances in TLC can be presented 
as the relationship between RM values and content of more 
polar component in mobile phase by the linear equation: 
RM=RM0 + m C; where C represents the volume fraction (% 
V/V) of the more polar component in mobile phase, m is 
slope of the linear plot and RM0 (intercept) the extrapolated 
value RM obtained at C=1%. The value of the intercept, RM0 
represents the lipophilicity of the examined substance. An-
other hydrophobicity parameter, the C0, can be calculated 
Table 1. Chromatographic hydrophobicity parameters of the investigated compounds
Compounds
Investigated ACE inhibitors
1 2 3 4 5
Cyclohexan – carbon tetrachloride
R
M
0 1.786±0.097 1.683±0.038 1.843±0.044 2.417±0.032 1.766±0.095
C
0
1.413 1.074 0.831 1.489 1.320
Cyclohexan – toluene
R
M
0 1.520±0.067 1.344±0.061 1.469±0.079 2.204±0.111 1.314±0.073
C
0
1.293 0.918 0.704 1.397 1.236
Cyclohexan - benzene
R
M
0 1.319±0.053 1.304±0.034 1.397±0.144 2.615±0.111 1.327±0.085
C
0
0.983 0.707 0.551 1.132 0.858
The numbers 1–5 denote the substances (Figure 1). R
M
0 and C
o
 are chromatographically obtained hydrophobicity parameters.
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as: C0=-RM0 / m [23, 24]. All experiments were carried out 
in triplicate, according to the general standards specified 
for this method. The relative standard deviations (RSD) 
for acquired absolute values were calculated and they all 
were under 1.00%. The average values of hydrophobicity 
parameters (RM0, C0) obtained in these investigations are 
presented in Table 1.
The ACE inhibitors molecular lipophilicity descrip-
tors – logP values were calculated using software package 
Virtual Computational Chemistry Laboratory [21]. Ex-
perimentally determined logPO/W (logPOctanol/Water) values of 
examined ACE inhibitors were obtained from the Clarke’s 
Analysis of Drugs and Poisons [20]. The different logP 
values of investigated ACE inhibitors were calculated using 
the software package Virtual Computational Chemistry 
Laboratory. In our previously published study [18] the 
selection of logPKOWWIN values was evaluated on the basis 
of its best agreement with experimental, from literature 
obtained logPO/W values (R2=0,999). The ACE inhibitors 
PPB data were collected from relevant references [5, 20]. 
The logPKOWWIN and logPO/W values of investigated ACE 
inhibitors are presented in Figure 1.
The Microsoft Excel 2003 was used to perform the sta-
tistical analysis of regression.
Figure 1. Investigated ACE inhibitors
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RESULTS
The protein binding data of investigated ACE inhibitors 
varied from negligible (lisinopril), through 24% (cilaz-
april), 55% (enalapril), 97% (quinapril) to 99% (fosino-
pril). The calculated logPKOWWIN values ranged from -0.94 
(lisinopril) to 6.61 (fosinopril).
In the first stage of the study, chromatographically es-
tablished hydrophobicity parameters C0, which are gener-
ally accepted as a reliable measure of lipophilicity were 
correlated with calculated logP values. The relations es-
tablished between chromatographic hydrophobicity pa-
rameters (C0) and logPKOWWIN values are shown in Table 2. 
Very good correlations (R2>0.86) were obtained for all 
used solvent systems (as proposed: the range of R2>0.79 in 
literature [25]) confirming hydrophobicity parameters C0 
obtained on cellulose layers under conditions of normal-
phase thin-layer chromatography, as suitable measure of 
ACE inhibitors lipophilicity. Since the best correlation 
(R2=0.916) was observed for cyclohexan – benzene mobile 
phase, hydrophobicity parameters C0 obtained with this 
solvent system will be considered in further correlation.
In the next stage of this study the relationship between 
calculated lipophilicity (logPKOWWIN values) as well as chro-
matographically obtained hydrophobicity parameters (C0) 
and PPB data of examined ACE inhibitors was investi-
gated. The following correlations were obtained:
PPB=14.400(±4.123) logPKOWWIN + 14.364 (±15.378)  (1)
n=5, R2=0.803, F=12.200
PPB=-168.651 (±53.782) C0 + 197.712 (±46.808)  (2)
n=5, R2=0.7662, F=9.833
The presented correlations can be considered as good, 
with high correlation coefficients (R2 higher than 0.75) 
and acceptable F values due to a limited number of com-
pounds. Next, the ACE inhibitors lipophilicity data, both 
calculated as well as chromatographically obtained could 
be considered as high-throughput screening techniques 
for the evaluation of selected compounds protein binding 
degree.
Even though good correlation coefficients (R2) were ob-
tained in both relations, unacceptable probability value 
with p>0.05 was found in relation between protein bind-
ing data and calculated logPKOWWIN values. Subsequently, 
although the correlation coefficient obtained in equa-
tion 2 (R2=0.7662) was slightly lower than R2 obtained in 
equation 1 (R2=0.803), better relationship with acceptable 
probability value (p<0.05) was observed between protein 
binding data and chromatographically obtained hydro-
phobicity parameters C0.
Values of PPB degree, collected from the relevant lit-
erature as well as predicted from relations with calculated 
logPKOWWIN (eq. 1) and hydrophobicity parameters, C0 val-
ues (obtained under conditions of NP-TLC) (eq. 2) are 
presented in Table 3 and at Graph 1.
DISCUSSION
The investigation of protein binding parameters has re-
ceived significant attention since its importance was rec-
ognized at the beginning of the 20th century. A number 
of authors suggest several in vitro assays that can be em-
ployed in determination of different drugs plasma pro-
tein binding degree. There are examples of separation 
techniques including equilibrium dialysis, ultrafiltration, 
ultracentrifugation and gel filtration [26, 27, 28]; recently 
developed chromatographic methods based on columns 
with immobilized human serum albumin [26, 29, 30] and 
capillary electrophoretic (CE) methods [27, 31, 32]. In a 
recently published study Ghafourian and Amin suggested 
in silico model for predicting PPB degree of compounds 
based on correlations with their computed molecular de-
scriptors. They established positive effect of lipophilicity 
measured by calculated logP descriptor on plasma protein 
binding [33].
Still, most of these methods have certain limitations 
and a new approach for a fast, reliable and cost-effective 
determination of plasma protein binding should be de-
veloped.
In this research several selected, most frequently pre-
scribed, ACE inhibitors (enalapril, quinapril, fosinopril, 
Table 2. Equations and correlation coefficients for C
0 
vs. logP
KOWWIN
 
values
Solvent system Equation R2
Cyclohexan – carbon 
tetrachloride C0 = 1.486 – 0.092 log PKOWWIN 0.867
Cyclohexan – toluene C
0
 = 1.387 – 0.098 log P
KOWWIN
0.864
Cyclohexan - benzene C
0
 = 1.072 – 0.080 log P
KOWWIN
0.916
Table 3. Data of plasma protein binding (PPB) collected from relevant 
literature and predicted from relations with
 
calculated logP
KOWWIN
 and 
chromatographic hydrophobicity parameters (C
0
 values)
ACE inhibitors PPBa PPB
predicted
b PPB
predicted
c
1 55 49.6 31.9
2 97 67.9 78.5
3 99 109.5 104.8
4 0 0.8 6.8
5 24 47.0 53.0
aPPB – collected from relevant literature; bPPB – predicted from relation with 
logP
KOWWIN
 values (eq. 1); cPPB – predicted from relation with C
0
 values (eq. 2)
Graph 1. Values of plasma protein binding (PPB) collected from rel-
evant literature (PPBa) [4] and predicted from relation (eq. 1) with
 
calculated logP
KOWWIN
 (PPBb) or relation (eq. 2) with chromatographic 
hydrophobicity parameters, C
0
 (PPBc)
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lisinopril, cilazapril) (Figure 1) were studied to establish 
the correlation between their plasma protein binding 
degree and lipophilicity data, calculated logP values or 
experimentally obtained hydrophobicity parameters C0 
with normal-phase thin-layer chromatography on cel-
lulose sorbent. In the first stage of this study, chromato-
graphically obtained C0 parameter was verified as a good 
measure of ACE inhibitors lipophilicity. Moreover, it was 
established that ACE inhibitors lipophilicity data correlate 
well with their plasma protein binding values. The good 
correlation (R2=0.7662) with acceptable probability value 
(p<0.05) was found between hydrophobicity parameters 
C0 and ACE inhibitors plasma protein binding data. The 
main advantage of cellulose – sorbent compared to silica 
gel – sorbent usually used in TLC, is that cellulose is easily 
available and cost-effective sorbent.
Present study can be considered as effective experimen-
tal assay which could be used as a fast, easy, cost-effective 
screening technique beside other previously proposed 
methodologies for PPB prediction. The proposed method-
ology has confirmed that lipophilicity is essential in drug’s 
PPB and could be regarded as new, additional, in vitro ap-
proach appropriate for modeling of PPB with lipophilicity 
of the investigated group of ACE inhibitors. In addition, 
besides simplicity and speed, this method could be consid-
ered as the economical high-throughput technique which 
does not require either expensive equipment investment 
or extensive analytical staff training.
CONCLUSION
High-quality correlation obtained between hydrophobic-
ity parameters C0 and protein binding data indicate that 
experimental techniques such as NP-TLC method can be 
suitable for the estimation of ACE inhibitors PPB degree.
The proposed approach based on hydrophobicity data 
experimentally obtained with a fast and easy chromato-
graphic technique is capable of screening ACE inhibitors 
PPB as well as new synthesized drugs and can be of great 
importance in drug research and development.
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КРАТАК САДРЖАЈ
Увод Ин хи би то ри ан ги о тен зин-кон вер ту ју ћег ен зи ма (ACE) 
су ве ли ка гру па ле ко ва из у зет но зна чај на у ле че њу хи пер-
тен зи је.
Циљ ра да Ана ли зи ра ни су иза бра ни АСЕ-ин хи би то ри (ена-
ла прил, кви на прил, фо зи но прил, ли зи но прил, ци ла за прил) 
ра ди по ста вља ња но вог при сту па по год ног за бр зу и јед-
но став ну про це ну ве зи ва ња за про те и не пла зме на осно ву 
њи хо вих па ра ме та ра ли по фил но сти.
Ме то де ра да Хро ма то граф ски па ра ме три хи дро фоб но-
сти (вред но сти C
0
) до би је ни су у усло ви ма нор мал но фа зне 
хро ма то гра фи је (NPTLC) на тан ком сло ју це лу ло зе, уз ко ри-
шће ње дво ком по нент них мо бил них фа за. Вред но сти па ра-
ме та ра ли по фил но сти ACE-ин хи би то ра (logP) из ра чу на те су 
по мо ћу софт вер ског па ке та Vir tual Com pu ta ti o nal Che mi stry 
La bo ra tory. По да ци о про цен ту ве зи ва ња ACE-ин хи би то ра за 
про те и не пла зме пре у зе ти су из од го ва ра ју ће ли те ра ту ре.
Ре зул та ти Про це нат ве зи ва ња за про те и не пла зме ис пи-
ти ва них АСЕ-ин хи би то ра био је у оп се гу од 0% (ли зи но-
прил) до 99% (фо зи но прил), док су вред но сти из ра чу на тих 
па ра ме та ра ли по фил но сти (вред но сти log P
KOW WIN
) би ле од 
-0,94 (ли зи но прил) до 6,61 (фо зи но прил). До би је не су за до-
во ља ва ју ће ко ре ла ци је из ме ђу вред но сти ве зи ва ња АСЕ-
ин хи би то ра за про те и не пла зме и из ра чу на тих log P
KOW WIN
 
вред но сти (ко е фи ци јент ко ре ла ци је R2 био је 0,8026), као 
и хро ма то граф ски до би је них па ра ме та ра хи дро фоб но сти, 
C
0
 (R2=0,7662). Иако су за до во ља ва ју ћи ко е фи ци јен ти ко-
ре ла ци је до би је ни у обе ре ла ци је, не при хва тљи ве вред но-
сти ве ро ват но ће (p>0,05) до би је не су за за ви сност из ме ђу 
вред но сти ве зи ва ња АСЕ-ин хи би то ра за про те и не пла зме 
и из ра чу на тих log P
KOW WIN
 вред но сти. Сто га се, узи ма ју ћи у 
об зир зах тев да вред но сти ве ро ват но ће бу ду ни же од 0,05, 
бо љом мо же сма тра ти за ви сност из ме ђу вред но сти ве зи ва-
ња АСЕ-ин хи би то ра за про те и не пла зме и хро ма то граф ски 
до би је них па ра ме та ра хи дро фоб но сти.
За кљу чак При ме на хи дро фоб них па ра ме та ра АСЕ-ин хи би-
то ра екс пе ри мен тал но до би је них у усло ви ма нор мал но фа-
зне хро ма то гра фи је на тан ком сло ју це лу ло зе за про це ну 
сте пе на њи хо вог ве зи ва ња за про те и не пла зме зна чај на је 
за раз вој и ис пи ти ва ње ле ко ва ове гру пе и про це ну њи хо ве 
би о ра спо ло жи во сти.
Кључ не ре чи: ин хи би то ри ан ги о тен зин-кон вер ту ју ћег ен-
зи ма (АСЕ-ин хи би то ри); ве зи ва ње за про те и не пла зме; ли-
по фил ност
Процена степена везивања инхибитора ангиотензин-конвертујућег ензима 
за протеине плазме применом хроматографски добијених параметара 
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